KEY TAKEAWAY: Since 1980 and the Bayh-Dole Act, drug companies can feed off research funded by the National Institutes of Health, which they acquire at late stages of development. As pointed out by former New England Journal of Medicine editor Dr. Marcia Angell, the big companies can either license the drugs or buy out small biotech companies carrying out NIH-funded research.[inlinetweet prefix=”” tweeter=”” suffix=””] In short, much of the research going into these products is funded by taxpayers, not pharmaceutical revenues.[/inlinetweet] Profits above taxpayers.